News for argenx SE (ARGX)

We came across a bullish thesis on argenx SE (ARGX) by Simvestor08 on r/valueinvesting on Reddit.. In this article, we will summarize the bulls’ thesis on ARGX.

Summary On June 3, 2025, argenx SE (ARGX), a prominent global immunology company, announced that its Chief Financial Officer, Karl Gubitz, will participate in a

Argenx (ARGX) recently experienced a decline in its stock price following the company's first-quarter earnings report. This downturn was primarily driven by inv

Citi analyst Samantha Semenkow maintains a positive outlook on Argenx (ARGX), indicating that worries about a deceleration in the Vyvgart launch are overstated.

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against the other growth...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Deutsche Bank has adjusted its price target for Argenx (ARGX), reducing it from EUR 575 to EUR 525, while maintaining a Hold rating on the company's shares. Thi

On May 9, 2025, Guggenheim analyst Yatin Suneja maintained a 'Buy' rating for the stock of argenx (ARGX). Despite retaining the positive rating, the firm announ

In the latest analyst update, Citigroup's Samantha Semenkow reaffirmed a

Argenx (ARGX) reported an impressive $790 million in net sales for the first quarter, surpassing market expectations despite typical seasonal fluctuations and u

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other best cancer stocks to invest in for long-term gain. Surging Cancer Cases and Costs Drive Growth in the Global Oncology Market […]

Guggenheim has revised its price target for Argenx (ARGX), lowering it from $1,100 to $1,065 while maintaining a Buy rating. The firm continues to acknowledge A

Citi analyst Samantha Semenkow has increased her price target for Argenx (ARGX) to $803, up from the previous target of $796, while maintaining a Buy rating on

Total Operating Income: $807 million in Q1 2025.Product Net Sales: $790 million, representing 99% growth compared to the prior year quarter.Regional Sales Brea

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Thursday. The Dow traded up 1.50% to 41,729.20 while the...

**media[617621]**

Baron Opportunity Fund declined in the first quarter of 2025, underperforming its benchmark, the Russell 3000 Growth Index. Read more here.

Baron Global Advantage Fund declined during the first quarter of 2025, underperforming its benchmark, the MSCI ACWI Index.

The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the market.